Evidence map›Paper›PMID 42412171›Full record

ReviewSeminars in immunopathology2026

PD-1⁺ CD8⁺ T cells: roles of PD-1 beyond an exhaustion marker.

Jingyi Chen, Zixiang Chen, Liangjie Xu, Jieting Jia, Ke Rui, Jie Tian

Abstract readReview
PubMed Publisher
In one paragraph

Review in Seminars in immunopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jingyi ChenDepartment of Laboratory Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Zixiang ChenDepartment of Laboratory Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Liangjie XuDepartment of Cardiology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, China.
Jieting JiaDepartment of Rheumatology, Northern Jiangsu Peoples Hospital Affiliated to Yangzhou University, Yangzhou, China. jiajieting000@163.com.
Ke RuiDepartment of Laboratory Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China. ruike@ujs.edu.cn.
Jie TianDepartment of Immunology, Jiangsu Key Laboratory of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, China. tianjie@ujs.edu.cn.

Funding

National Natural Science Foundation of China 82171771National Natural Science Foundation of China 82271854National Natural Science Foundation of China 82300283
6 · The paper itself

Abstract

Programmed cell death protein 1 (PD-1) has long been considered a central molecule in CD8⁺ T cell exhaustion and immunosuppression. However, recent studies have revealed that PD-1⁺CD8⁺ T cells are not a homogeneous population of terminally dysfunctional cells, but rather constitute key immune cells with significant heterogeneity and functional plasticity within tissue immune microenvironments. PD-1 signaling operates throughout multiple stages of CD8⁺ T cell biology, including thymic development, peripheral activation, chronic antigen stimulation, and tissue residency. By finely regulating T cell receptors (TCRs) signal strength, metabolic state, and transcriptional programs, it deeply participates in cell fate decisions while limiting immunopathology. In chronic infections and tumors, persistent antigen stimulation drives PD-1⁺CD8⁺ T cells to form an exhaustion lineage with a defined differentiation hierarchy, encompassing stem-like precursor cells, effector-like transitional cells, and terminally exhausted cells. PD-1 is not only a characteristic marker of this lineage but also a critical regulatory node through which immune checkpoint blockade therapy exerts its therapeutic effects. Furthermore, in contexts such as tissue-resident memory T cells (T

Indexed as

CD8-Positive T-LymphocytesProgrammed Cell Death 1 ReceptorAnimalsBiomarkersHumansNeoplasmsSignal TransductionT-Cell ExhaustionT-Lymphocyte SubsetsBiomarkersProgrammed Cell Death 1 ReceptorCD8⁺ T cellGZMKPD-1PD-1+ CD8+ TRMPD-L1TRM

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.